



European Patent
Office

SUPPLEMENTARY
EUROPEAN SEARCH REPORT

0776161

Application Number
EP 95 92 9543

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.6)
P,X	WEI M X ET AL: "EXPERIMENTAL TUMOR THERAPY IN MICE USING THE CYCLOPHOSPHAMIDE-ACTIVATING CYTOCHROME P450 2B1 GENE" HUMAN GENE THERAPY, vol. 5, no. 8, August 1994, pages 969-978, XP002040463 * see the whole document *	1,2, 4-10,12, 13	C12N9/02 A61K48/00 A01N43/04 A61K31/70 C12N5/00 C12N15/00 C12N15/09 C12N15/63 C12N15/74 C07K1/00 C07K14/00
P,X	WO 95 05835 A (BAYLOR COLLEGE MEDICINE ;CHEN SHU HSIA (US); WOO SAVIO L C (US)) 2 March 1995 *see p.2, l. 17-21; claims 1,16,39,55*	2-4,8	
Y	TIANO H F ET AL: "RETROVIRAL MEDIATED EXPRESSION OF HUMAN CYTOCHROME P450 2A6 IN C3H/10T1/2 CELLS CONFERS TRANSFORMABILITY BY 4-(METHYLNITROSAMINO)-1-(3-PYRIDYL)-1-BUTANONE (NNK)" CARCINOGENESIS, vol. 14, no. 7, July 1993, pages 1421-1427, XP002040462 *see the abstract and discussion *	1-13	
Y	US 5 164 313 A (GELBOIN HARRY V ET AL) 17 November 1992 * see in particular col. 7, line 45 - col. 8 *	1-13	
			TECHNICAL FIELDS SEARCHED (Int.Cl.6)
			C12N A61K
The supplementary search report has been based on the last set of claims valid and available at the start of the search.			
Place of search MUNICH		Date of completion of the search 11 February 1999	Examiner Isert, B
CATEGORY OF CITED DOCUMENTS			
X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document	

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 95 92 9543

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.
The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

11-02-1999

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9505835 A	02-03-1995	US 5631236 A	20-05-1997
		AU 677430 B	24-04-1997
		AU 7677694 A	21-03-1995
		CA 2169260 A	02-03-1995
		EP 0719147 A	03-07-1996
		JP 9504784 T	13-05-1997

US 5164313 A	17-11-1992	US 5506131 A	09-04-1996
		US 5506138 A	09-04-1996
		US 5660986 A	26-08-1997
		US 5356806 A	18-10-1994

CLAIMS

- ~ 1, 70
- 5 1. The use of a viral vector, said vector carrying a cytochrome P450 gene, wherein expression of the gene product renders central nervous system tumour cells sensitive to a chemotherapeutic agent independent of the cell cycle of said tumour cells, in the manufacture of a medicament for the treatment of central nervous system tumours.
- 10 2. The use of a viral vector, said vector carrying a cytochrome P450 gene, wherein the expression product of the gene activates a chemotherapeutic agent to a cytotoxic metabolite, in the manufacture of a medicament for the treatment of malignant tumours.
- 15 3. The use of a viral vector, said vector carrying a cytochrome P450 gene, wherein expression of the gene product renders peripheral tumour cells sensitive to a chemotherapeutic agent independent of the cell cycle of said tumour cells, in the manufacture of a medicament for the treatment of peripheral tumours.
- ~ 20
- 25 2 4. The use as claimed in any one of claims 1 to 3, wherein said cytochrome gene is P450 2B1, P450 2B6, P450 2A6, P450 2C6, P450 2C8, P450 2C9, P450 2C11, or P450 3A4.
- 30 3 5. The use as claimed in claim 4, wherein said cytochrome gene is P450 2B1.
- 4 6. The use as claimed in any one of claims 1 to 5, wherein said chemotherapeutic agent is cyclophosphamide or ifosphamide.

7. The use as claimed in claim 6, wherein said
chemotherapeutic agent is cyclophosphamide. /

5 8. The use as claimed in any one of claims 1 to 7,
wherein said viral vector is a retrovirus. 9

10 9. The use as claimed in any one of claims 1, or 4 to
8, wherein said central nervous system tumour cells are
astrocytomas, oligodendrogliomas, meningiomas,
neurofibromas, glioblastomas, ependymomas, Schwannomas,
or neurofibrosarcomas. 8

15 10. The use as claimed in any one of claims 2 or 4 to 8
wherein the malignant tumour is located in the central
nervous system. 17

20 11. The use as claimed in any one of claims 3 to 8,
wherein said peripheral tumor cells are breast tumor
cells. 31

20 12. The use of a viral vector, said vector carrying a
cytochrome P450 2B1 gene, wherein expression of the gene
product renders central nervous system tumour cells
sensitive to cyclophosphamide independent of the cell
25 cycle of the tumour cells, in the manufacture of a
medicament for the treatment of central nervous system
tumours.

30 21 13. The use of a viral vector, said vector carrying a
cytochrome P450 2B1 gene, wherein the expression product
of the gene activates cyclophosphamide to a cytotoxic
metabolite, in the manufacture of an agent to enhance the
efficiency of a chemotherapeutic agent in treating
malignant tumours.

123(1) ok